Trinta John
Known title: DirectorCIK: 0002043240
Associated companies
Transaction History
| RUN | ▲ Buy | Grant | 9,687 | $0 | 1/2/2026 | View on chart |
| RUN | ▲ Buy | Grant | 17,357 | $0 | 1/2/2025 | View on chart |
| RUN | ▲ Buy | Grant | 1,973 | $0 | 10/31/2024 | View on chart |
| RUN | ▲ Buy | Grant | 9,687 | $0 | 1/2/2026 | View on chart |
| RUN | ▲ Buy | Grant | 17,357 | $0 | 1/2/2025 | View on chart |
| RUN | ▲ Buy | Grant | 1,973 | $0 | 10/31/2024 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Sunrun analysts lower price targets amid valuation debate
Citigroup, Barclays and Goldman Sachs all kept their coverage of Sunrun but reduced their price targets to $14, $12 and $11 respectively. A separate valuation estimate says the stock may be as much as 52% below its intrinsic value ahead of the upcoming Q3 earnings release. Yahoo reported unusual options activity that could reflect multimillion‑dollar positions. The mix of lower targets and potential undervaluation adds mixed signals for the stock.
Sunrun analysts lower price targets amid valuation debate. Citigroup, Barclays and Goldman Sachs all kept their coverage of Sunrun but reduced their price targets to $14, $12 and $11 respectively. A separate valuation estimate says the stock may be as much as 52% below its intrinsic value ahead of the upcoming Q3 earnings release. Yahoo reported unusual options activity that could reflect multimillion‑dollar positions. The mix of lower targets and potential undervaluation adds mixed signals for the stock.